| Today’s Big NewsFeb 21, 2024 |
| By Fraiser Kansteiner PhRMA revealed that Gilead CEO Daniel O’Day has donned the mantle as chair of the board of directors, replacing Novartis chief Vas Narasimhan, who held the position for much of 2023. |
|
|
|
By Gabrielle Masson,Max Bayer We really didn't want to have to create another Layoff Tracker this year. But here we are, launching the third annual iteration tracking biopharma layoffs. |
By Andrea Park More than half a decade after Medtronic wrapped up its $1.6 billion buyout of Mazor Robotics, at least one former Mazor employee is still grappling with the aftermath of the deal. |
By Kevin Dunleavy When a federal appeals court rejected United Therapeutics’ attempt to revive an invalidated patent on its aging pulmonary arterial hypertension drug Tyvaso, it cleared one hurdle for the FDA to approve a rival treatment from the North Carolina-based Liquidia Corporation. But now United is using a different tactic to thwart the potential competitor. |
|
Thursday, March 7, 2024 | 2pm ET / 11am PT Join us for this discussion on the future of cloud computing in healthcare. Learn key insights on the investments being made to advance research and commercial efforts. We will explore topics such as data sharing without data movement, the future of analytics and privacy, the use of ML models for lookalike audiences supported by cloud computing, and more. Register now. 
|
|
By Helen Floersh NodThera’s lead clinical-stage drug for Parkinson’s is almost as effective at inducing weight loss as Novo Nordisk’s blockbuster GLP-1 receptor agonist Wegovy, new data shows. |
By Conor Hale The Symani system, with its two robotic arms, mimics the dexterity of the human hand on a much smaller scale while smoothing out tremors. |
By Fraiser Kansteiner AstraZeneca CEO Pascal Soriot’s compensation package makes him the current top contender for 2023’s highest-paid pharma CEO in Europe. Still, as in years past, not everyone is pleased with Soriot’s 2023 windfall. |
By James Waldron AstraZeneca's David Fredrickson spoke to Fierce Biotech as the FDA accepted an application for the company’s TROP2-directed ADC datopotamab deruxtecan. |
By Andrea Park In much the same way that Cagent Vascular’s flagship device is designed to help open up blocked arteries to promote blood flow, a recent round of funding for the startup is now slated to widen the device’s path in the commercial market. |
By Angus Liu GSK’s long-acting HIV regimen Cabenuva has already shown it works as well as daily oral therapies in patients who have the virus under control. Now, the injection has beaten daily drugs in individuals who’ve faced issues adhering to their medications. |
By James Waldron Bavarian Nordic may be celebrating its most profitable year yet on the back of mpox vaccine sales, but that hasn’t stopped the Danish biotech from streamlining its portfolio. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," Max Bayer from Fierce Biotech explores the future of gene editing in an interview with the CEO of Verve Therapeutics. |
|
|---|
|
|
|
Wednesday, March 13, 2024 | 11:00am ET/ 8:00am PT Extractables and leachables are a hot topic in the pharmaceutical industry today. As single-use systems, devices, and routes of administration evolve, it is important to have a strategy that helps ensure you choose proper equipment and materials, file on time, avoid repeat studies, and more. Save your spot to be a part of this insightful discussion! 
|
|
Whitepaper This paper offers a detailed review of key events and developments in the oncology market during 2023. It’s a helpful “status report” that informs how the market is likely to evolve in 2024. It covers, vaccines, radiopharmaceuticals, ADCs, CAR-Ts, bi-specifics, & more. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
| |
|
